Cellectis SA
CLLS3.240USD
+0.110+3.51%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
234.33MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cellectis SA Unternehmen
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA Informationen
BörsenkürzelCLLS
Name des UnternehmensCellectis SA
IPO-datumFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Anzahl der mitarbeiter224
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 06
Addresse8, rue de la Croix Jarry
StadtPARIS
BörseNASDAQ Global Market Consolidated
LandFrance
Postleitzahl75013
Telefon33181691600
Websitehttps://www.cellectis.com/
BörsenkürzelCLLS
IPO-datumFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Führungskräfte von Cellectis SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 20 hours ago
Aktualisiert: 20 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Long Focus Capital Management LLC
6.52%
B Group, Inc.
4.50%
UBS Asset Management (Americas) LLC
2.59%
UBS Asset Management Switzerland AG
1.99%
UBS Asset Management (Switzerland)
1.80%
Andere
82.59%
Aktionäre
Aktionäre
Anteil
Long Focus Capital Management LLC
6.52%
B Group, Inc.
4.50%
UBS Asset Management (Americas) LLC
2.59%
UBS Asset Management Switzerland AG
1.99%
UBS Asset Management (Switzerland)
1.80%
Andere
82.59%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
11.60%
Hedge Fund
6.57%
Investment Advisor/Hedge Fund
0.40%
Research Firm
0.19%
Andere
81.24%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
72
13.58M
18.77%
-9.58M
2025Q2
78
18.10M
25.03%
-2.47M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Long Focus Capital Management LLC
4.72M
6.52%
--
--
Jun 30, 2025
B Group, Inc.
3.26M
4.5%
--
--
Jun 30, 2025
UBS Asset Management (Americas) LLC
1.87M
2.59%
+27.88K
+1.51%
Jun 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
UBS Asset Management (Switzerland)
1.30M
1.8%
-1.57M
-54.65%
Jun 30, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Jun 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jan 31, 2025
LPL Financial LLC
85.66K
0.12%
+915.00
+1.08%
Jun 30, 2025
Morgan Stanley & Co. International Plc
73.19K
0.1%
+6.00K
+8.93%
Jun 30, 2025
AllianceBernstein L.P.
54.64K
0.08%
+32.83K
+150.56%
Jun 30, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Anteil0%
Avantis International Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
